2
Key Points
Key Points
➤ This pocket guide updates the 2020 ASCO guideline on systemic
therapy for patients with stage IV non-small cell lung cancer (NSCLC).
➤ Recommendations apply to patients with known epidermal growth
factor receptor- (EGFR ) and anaplastic lymphoma kinase- (ALK)
status.
➤ Recommendations are conditional on the basis of histology,
programmed death ligand 1 (PD-L1) status, and/or the presence or
absence of contraindications.
Diagnosis
Table 1. Definitions of PD-L1 Tumor Proportion Score (TPS)
Level
Definition PD-L1 Level (%)
High ≥50%
Low positive ≥1% – 49%
Negative <1%
0%
Unknown
Recommendation Grading
Type Benefit/harm Evidence Quality
Strength of
Recommendation
EB Evidence-
based
B Benefits
outweigh harms
H High Strong
CB
Consensus-
based
H Harms
outweigh
benefits
I Intermediate Moderate
IC Informal
consensus
B/H Relative balance
of benefits and
harms
L Low Weak
U Benefits/harms
ratio uncertain
Ins Insufficient
